Hepion Pharmaceuticals reported a net loss of $6.6 million for the nine months ended September 30, 2026, compared to a $7.6 million loss in the prior year period. The company's financial position shows a stockholders' deficit of $4.0 million, and management highlighted significant uncertainties regarding their ability to raise additional capital to continue as a going concern.
Hepion Pharmaceuticals Signs $4.38M M&A Deal with Gravitas Life Sciences, LLC
Hepion Pharmaceuticals completed the acquisition of all issued and outstanding membership interests of Gravitas Life Sciences, LLC from Gravitas Collective Corp. The total consideration consisted of $2.0 million in cash, 25,000,000 shares of common stock valued at $2.25 million, and an additional $135,000 payment. The transaction is classified as a related party transaction as several Hepion directors are also officers of Gravitas Life Sciences.
Hepion Pharmaceuticals Insider Danina Fisher Buys $10K of Stock
Danina Fisher bought 200,000 shares of Hepion Pharmaceuticals, Inc. at $0.05 a share, worth $10K in total on Sep 29, 2026. Shares held after the trade: 200,000.
Hepion Pharmaceuticals filed a Certificate of Amendment to its Certificate of Incorporation to increase the authorized number of shares of common stock to 750,000,000. The amendment became effective upon filing on October 1, 2026. This action increases the company's capacity for future share issuances but does not represent an active capital raise in this filing.